About EAST INDIA PHARMACEUTICAL WORKS LIMITED Unlisted Shares
East India Pharmaceutical Works Limited (EIPW) is one of the oldest pharmaceutical companies in India, Founded on 27 April 1936, it is involved in the Manufacturing of Healthcare Products. It is registered at the Registrar of Companies in Kolkata. The authorized equity share capital of the company is Rs. 10,00,00,000 and the paid-up capital is Rs. 6,67,45,180.
The Company has over 87 years of experience and has a focused “people-centric approach” which enabled it to evolve with ever-changing healthcare needs and it offers high-quality advanced medicines for modern-day health complexities.
Along with its high-quality products and experienced medical and research team, backed by the most advanced and precise equipment and infrastructure, the company ensures international quality standards at every stage of production. East India Pharmaceutical is focused on using cost-effective processes to produce high-volume formulations. The company has achieved GMP, WHO-GMP, and GLP certifications.
INCORPORATION DETAILS
|
CIN |
U24231WB1936PLC008598 |
|
Registration Date |
27 April 1936 |
|
Company Name |
EAST INDIA PHARMACEUTICAL WORKS LIMITED |
|
Email Address |
dcs@eastindiapharma.org |
|
Category/Sub-category of the Company |
Company Limited by Shares/Non-Government Company |
|
Class of Company |
Public |
|
Registration Number |
8598 |
|
Banker |
Punjab National Bank |
|
Address of the Registered office & contact details |
6, Nandalal Bose Sarani, Kolkata 700 071 |
|
Statutory Auditors |
M/s APS Associates Chartered Accountants |
|
Cost Auditors |
M/s DGM & Associates Cost Accountants |
|
Company Secretary |
Ms. Jayeeta Sarkar |
|
Registrar and Share Transfer Agent |
C B Management Services (P) Ltd. P-22, Bondel Road, Kolkata - 700 019 |
|
Listing Status |
Unlisted |
PARTICULAR OF SUBSIDIARY COMPANIES
|
Name of the Company |
Subsidiary |
% of shares held |
|
Qasar Healthcare Private Limited |
Subsidiary |
99.5% |
BOARD OF DIRECTORS
Mr. Debarshi Duttagupta (Managing Director)
Mrs. Satarupa Mukherjee (Executive Director)
Prof. (Dr.) Ranabir Mukherjee
Mr. Probir Roy (Chairman)
Mr. Dilip Samadar (Member)
Prof. (Dr.) Suman Kumar Mukerjee
Mr. Sukamal Chandra Basu (Member)
Mr. Chiraranjan Addy
Prof. (Dr.) Himadri Sengupta
Dr. Abhijit Banerjee
Dr.Tapas Raychaudhury
Mrs. Indrani Sen
Mrs. Sanghamitra Duttagupta
Mrs. Trishna Guha
Principal Business Activities of the Company
|
Name & Description of main products/services |
NIC Code of the Product /service |
% to total turnover of the company |
|
Manufacture of bulk drugs, Manufacture & sale of formulations & Trading Activities |
210 |
100% |
SHAREHOLDING PATTERN (As of 31-03-2021)
|
S. No. |
Shareholder’s Category |
No. of Shares |
% of total Shares of the company |
|
1 |
PROMOTERS |
20,09,361 |
30.11% |
|
2 |
PUBLIC |
46,65,497 |
69.89% |
|
|
Total |
66,74,858 |
100% |
Industry Outlook
The company is one of the oldest pharmaceutical companies in India that develops, manufactures, and markets high-quality medicines. The company has two manufacturing plants, one in Durgapur and one in Kolkata, with cutting-edge production facilities. The rapid spread of the COVID-19 pandemic had a significant impact on global economic activity. In India, like other countries around the world, has been severely impacted. IMF forecasts a 4.5 percent contraction in India for 2021. Finance Minister announced an additional outlay of Rs. 1,97,000 crore (USD 26,578.3 million) for the pharmaceutical Production Linked Incentive (PLI) scheme.
FY 2020-2021 Highlights of Company
